Furthermore, metformin treatment was associated with the suppression of AGEs, ET-1, TNF-α, iNOS, dyslipidemia, as well as femoral artery ultrastructural damage that had been induced by diabetes (Figure 5). Here, EDN1 is linked to metabolic syndrome.